Division of Cardiovascular Disease, Cooper University Health Care, Cooper Medical School of Rowan University, Camden, New Jersey, USA.
Department of Medicine, Westchester Medical Center, Valhalla, New York, USA.
J Cardiovasc Electrophysiol. 2022 Dec;33(12):2585-2598. doi: 10.1111/jce.15708. Epub 2022 Nov 24.
Data on utilization, major complications, and in-hospital mortality of catheter ablation (CA) for sarcoidosis-related ventricular tachycardia (VT) are limited. We sought to determine the outcomes of sarcoidosis-related VT, and incidence and predictors of complications associated with the CA procedure.
We queried the 2002-2018 National Inpatient Sample database to identify patients aged ≥18 years with sarcoidosis admitted with VT. A 1:3 propensity score-matched (PSM) analysis was used to compare patient outcomes between CA and medically managed groups. Multivariable regression was performed to determine independent predictors of in-hospital mortality and procedural complications associated with the CA procedure.
Of 3220 sarcoidosis patients with VT, 132 (4.1%) underwent CA. Patients who underwent CA were younger, male predominant, more likely Caucasian, had differences in baseline comorbidities including more likely to have heart failure, less likely to have prior myocardial infarction, COPD, or severe renal disease, had a higher mean household income, and more likely admitted to a larger/urban teaching hospital. After PSM, we examined 106 CA cases and 318 medically managed cases. There was a trend toward a lower in-hospital mortality rate in the CA group when compared to the medically managed group (1.9% vs. 6.6%, p = 0.08). The most common complications were pericardial drainage (5.3%), postoperative hemorrhage (3.8%), accidental puncture periprocedure (3.0%), and cardiac tamponade (2.3%). Independent predictors of in-hospital mortality and procedural complications among the CA group included congestive heart failure (odds ratio [OR], 13.2; 95% confidence interval [CI], 1.7-104.2) and mild to moderate renal disease (OR, 3.9; 95% CI, 1.1-13.3).
Compared to patients with sarcoidosis-related VT who received medical therapy alone, those who underwent CA have a trend for a lower mortality rate despite procedure-related complications occurring as high as 9.1%. Additional studies are recommended to better evaluate the benefits and risks of VT ablation in this group.
关于因结节病导致的室性心动过速(VT)患者接受导管消融(CA)治疗的应用、主要并发症和院内死亡率的数据有限。我们旨在明确因结节病导致的 VT 的治疗结果,以及 CA 治疗相关并发症的发生率和预测因素。
我们从 2002 年至 2018 年国家住院患者样本数据库中查询年龄≥18 岁、因 VT 入院且患有结节病的患者。我们使用 1:3 的倾向评分匹配(PSM)分析比较 CA 治疗组和药物治疗组的患者结局。多变量回归用于确定与 CA 治疗相关的院内死亡率和并发症的独立预测因素。
在 3220 名患有 VT 的结节病患者中,有 132 名(4.1%)接受了 CA 治疗。接受 CA 治疗的患者更年轻,男性居多,更可能为白人,基础合并症存在差异,包括更有可能患有心力衰竭,不太可能患有心肌梗死、COPD 或严重肾脏疾病,平均家庭收入较高,更有可能入住较大的/教学医院。进行 PSM 后,我们检查了 106 例 CA 病例和 318 例药物治疗病例。与药物治疗组相比,CA 组的院内死亡率呈下降趋势(1.9%比 6.6%,p=0.08)。最常见的并发症是心包引流(5.3%)、术后出血(3.8%)、围手术期意外穿刺(3.0%)和心脏压塞(2.3%)。CA 组院内死亡率和并发症的独立预测因素包括充血性心力衰竭(比值比[OR],13.2;95%置信区间[CI],1.7-104.2)和轻度至中度肾功能不全(OR,3.9;95% CI,1.1-13.3)。
与单独接受药物治疗的因结节病导致的 VT 患者相比,尽管发生了高达 9.1%的与治疗相关的并发症,但接受 CA 治疗的患者死亡率呈下降趋势。建议开展更多研究,以更好地评估该组患者 VT 消融的获益和风险。